Methyl inosine monophosphate

A potential immunotherapeutic for early human immunodeficiency virus (HIV) infection

John W. Hadden, Joseph Ongradi, Steven Specter, Robert Nelson, Marina Sosa, Craig Monell, Mette Strand, Alfredo Giner-Sorolla, Elba M. Hadden

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

MIMP is a new thymomimetic purine under development for immunorestorative therapy. Lymphocytes were obtained from eight patients with acquired immunodeficiency disease (AIDS), eight with symptomatic pre-AIDS (ARC), and 22 normal controls and were stimulated in vitro with phytohemagglutinin (PHA). AIDS patients (mean CD4 counts of 40) showed PHA responses <10% of control while ARC patients (mean CD4 counts of 544) showed responses approximately 50% of the control responses. MIMP (0.1, 1, 10 and 100 μg/ml) progressively augmented the PHA responses in all these groups. The augmentation of the responses of the leukocytes of AIDS patients while statistically significant was minimal. The augmentation of the responses of ARC patients was significant and their maximal responses approached control levels. The effect of 1 μg/ml MIMP was comparable with that observed with indomethacin (10-6 M) and interleukin-2 (IL2 - 4 units/ml) and was additive with each of these stimulants. In a parallel manner, MIMP restored the suppression of control lymphocytes induced by the immunosuppressive 17 amino acid fragment of the P41 peptide of HIV. In vivo experiments showed that MIMP significantly delayed death in a murine FLV AIDS model at a dose of 1 mg/kg by the oral or parenteral route. MIMP is under preclinical development for early HIV disease to forestall progression to AIDS by attenuating virus-induced immunosuppression.

Original languageEnglish (US)
Pages (from-to)555-563
Number of pages9
JournalInternational Journal of Immunopharmacology
Volume14
Issue number4
DOIs
StatePublished - 1992
Externally publishedYes

Fingerprint

Virus Diseases
HIV
AIDS-Related Complex
Phytohemagglutinins
CD4 Lymphocyte Count
Interleukin-2
Lymphocytes
Peptide Fragments
Immunosuppressive Agents
Indomethacin
Immunosuppression
methyl inosine monophosphate
Leukocytes
Amino Acids

ASJC Scopus subject areas

  • Immunology
  • Pharmacology

Cite this

Methyl inosine monophosphate : A potential immunotherapeutic for early human immunodeficiency virus (HIV) infection. / Hadden, John W.; Ongradi, Joseph; Specter, Steven; Nelson, Robert; Sosa, Marina; Monell, Craig; Strand, Mette; Giner-Sorolla, Alfredo; Hadden, Elba M.

In: International Journal of Immunopharmacology, Vol. 14, No. 4, 1992, p. 555-563.

Research output: Contribution to journalArticle

Hadden, John W. ; Ongradi, Joseph ; Specter, Steven ; Nelson, Robert ; Sosa, Marina ; Monell, Craig ; Strand, Mette ; Giner-Sorolla, Alfredo ; Hadden, Elba M. / Methyl inosine monophosphate : A potential immunotherapeutic for early human immunodeficiency virus (HIV) infection. In: International Journal of Immunopharmacology. 1992 ; Vol. 14, No. 4. pp. 555-563.
@article{5f0ad15bd9f841d7850938dec77c84fb,
title = "Methyl inosine monophosphate: A potential immunotherapeutic for early human immunodeficiency virus (HIV) infection",
abstract = "MIMP is a new thymomimetic purine under development for immunorestorative therapy. Lymphocytes were obtained from eight patients with acquired immunodeficiency disease (AIDS), eight with symptomatic pre-AIDS (ARC), and 22 normal controls and were stimulated in vitro with phytohemagglutinin (PHA). AIDS patients (mean CD4 counts of 40) showed PHA responses <10{\%} of control while ARC patients (mean CD4 counts of 544) showed responses approximately 50{\%} of the control responses. MIMP (0.1, 1, 10 and 100 μg/ml) progressively augmented the PHA responses in all these groups. The augmentation of the responses of the leukocytes of AIDS patients while statistically significant was minimal. The augmentation of the responses of ARC patients was significant and their maximal responses approached control levels. The effect of 1 μg/ml MIMP was comparable with that observed with indomethacin (10-6 M) and interleukin-2 (IL2 - 4 units/ml) and was additive with each of these stimulants. In a parallel manner, MIMP restored the suppression of control lymphocytes induced by the immunosuppressive 17 amino acid fragment of the P41 peptide of HIV. In vivo experiments showed that MIMP significantly delayed death in a murine FLV AIDS model at a dose of 1 mg/kg by the oral or parenteral route. MIMP is under preclinical development for early HIV disease to forestall progression to AIDS by attenuating virus-induced immunosuppression.",
author = "Hadden, {John W.} and Joseph Ongradi and Steven Specter and Robert Nelson and Marina Sosa and Craig Monell and Mette Strand and Alfredo Giner-Sorolla and Hadden, {Elba M.}",
year = "1992",
doi = "10.1016/0192-0561(92)90116-3",
language = "English (US)",
volume = "14",
pages = "555--563",
journal = "International Immunopharmacology",
issn = "1567-5769",
publisher = "Elsevier",
number = "4",

}

TY - JOUR

T1 - Methyl inosine monophosphate

T2 - A potential immunotherapeutic for early human immunodeficiency virus (HIV) infection

AU - Hadden, John W.

AU - Ongradi, Joseph

AU - Specter, Steven

AU - Nelson, Robert

AU - Sosa, Marina

AU - Monell, Craig

AU - Strand, Mette

AU - Giner-Sorolla, Alfredo

AU - Hadden, Elba M.

PY - 1992

Y1 - 1992

N2 - MIMP is a new thymomimetic purine under development for immunorestorative therapy. Lymphocytes were obtained from eight patients with acquired immunodeficiency disease (AIDS), eight with symptomatic pre-AIDS (ARC), and 22 normal controls and were stimulated in vitro with phytohemagglutinin (PHA). AIDS patients (mean CD4 counts of 40) showed PHA responses <10% of control while ARC patients (mean CD4 counts of 544) showed responses approximately 50% of the control responses. MIMP (0.1, 1, 10 and 100 μg/ml) progressively augmented the PHA responses in all these groups. The augmentation of the responses of the leukocytes of AIDS patients while statistically significant was minimal. The augmentation of the responses of ARC patients was significant and their maximal responses approached control levels. The effect of 1 μg/ml MIMP was comparable with that observed with indomethacin (10-6 M) and interleukin-2 (IL2 - 4 units/ml) and was additive with each of these stimulants. In a parallel manner, MIMP restored the suppression of control lymphocytes induced by the immunosuppressive 17 amino acid fragment of the P41 peptide of HIV. In vivo experiments showed that MIMP significantly delayed death in a murine FLV AIDS model at a dose of 1 mg/kg by the oral or parenteral route. MIMP is under preclinical development for early HIV disease to forestall progression to AIDS by attenuating virus-induced immunosuppression.

AB - MIMP is a new thymomimetic purine under development for immunorestorative therapy. Lymphocytes were obtained from eight patients with acquired immunodeficiency disease (AIDS), eight with symptomatic pre-AIDS (ARC), and 22 normal controls and were stimulated in vitro with phytohemagglutinin (PHA). AIDS patients (mean CD4 counts of 40) showed PHA responses <10% of control while ARC patients (mean CD4 counts of 544) showed responses approximately 50% of the control responses. MIMP (0.1, 1, 10 and 100 μg/ml) progressively augmented the PHA responses in all these groups. The augmentation of the responses of the leukocytes of AIDS patients while statistically significant was minimal. The augmentation of the responses of ARC patients was significant and their maximal responses approached control levels. The effect of 1 μg/ml MIMP was comparable with that observed with indomethacin (10-6 M) and interleukin-2 (IL2 - 4 units/ml) and was additive with each of these stimulants. In a parallel manner, MIMP restored the suppression of control lymphocytes induced by the immunosuppressive 17 amino acid fragment of the P41 peptide of HIV. In vivo experiments showed that MIMP significantly delayed death in a murine FLV AIDS model at a dose of 1 mg/kg by the oral or parenteral route. MIMP is under preclinical development for early HIV disease to forestall progression to AIDS by attenuating virus-induced immunosuppression.

UR - http://www.scopus.com/inward/record.url?scp=0026691309&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026691309&partnerID=8YFLogxK

U2 - 10.1016/0192-0561(92)90116-3

DO - 10.1016/0192-0561(92)90116-3

M3 - Article

VL - 14

SP - 555

EP - 563

JO - International Immunopharmacology

JF - International Immunopharmacology

SN - 1567-5769

IS - 4

ER -